相似文献
1
Old and new: appropriate dosing for neonatal antifungal drugs in the nursery.
Early Hum Dev. 2013 Jun;89 Suppl 1(0 1):S25-7. doi: 10.1016/S0378-3782(13)70009-4.
2
Antifungal pharmacotherapy for neonatal candidiasis.
Semin Perinatol. 2003 Oct;27(5):365-74. doi: 10.1016/s0146-0005(03)00060-0.
3
Invasive candidiasis in the ICU: evidence based and on the edge of evidence.
Mycoses. 2008 Sep;51 Suppl 2:25-45. doi: 10.1111/j.1439-0507.2008.01571.x.
4
From bench to bedside: Perspectives on the utility of pharmacokinetics/pharmacodynamics in predicting the efficacy of antifungals in invasive candidiasis.
Mycoses. 2020 Aug;63(8):854-858. doi: 10.1111/myc.13121. Epub 2020 Jun 13.
5
Advances in the treatment of invasive neonatal candidiasis.
Expert Opin Pharmacother. 2015 May;16(7):1035-48. doi: 10.1517/14656566.2015.1031108. Epub 2015 Apr 5.
6
Severe Candida albicans panophthalmitis treated with all available and potentially effective antifungal drugs: fluconazole, liposomal amphotericin B, caspofungin, and voriconazole.
Scand J Infect Dis. 2006;38(10):950-1. doi: 10.1080/00365540600617041.
7
Antifungals in systemic neonatal candidiasis.
Drugs. 2004;64(9):949-68. doi: 10.2165/00003495-200464090-00003.
8
Antifungal agents in neonates: issues and recommendations.
Paediatr Drugs. 2007;9(5):311-21. doi: 10.2165/00148581-200709050-00004.
9
Antifungal therapy and outcomes in infants with invasive Candida infections.
Pediatr Infect Dis J. 2012 May;31(5):439-43. doi: 10.1097/INF.0b013e3182467a72.
10
Voriconazole for candidosis: an important addition?
Lancet. 2005;366(9495):1413-4. doi: 10.1016/S0140-6736(05)67579-4.
引用本文的文献
1
"Amber in chamber" an enigmatous right atrial mass in a neonate.
Saudi J Anaesth. 2015 Oct-Dec;9(4):477-9. doi: 10.4103/1658-354X.159482.
本文引用的文献
1
Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011.
Clin Infect Dis. 2012 Nov 15;55(10):1352-61. doi: 10.1093/cid/cis697. Epub 2012 Aug 14.
2
Therapeutic monitoring of voriconazole in children less than three years of age: a case report and summary of voriconazole concentrations for ten children.
Pediatr Infect Dis J. 2012 Jun;31(6):632-5. doi: 10.1097/INF.0b013e31824acc33.
3
Antifungal therapy and outcomes in infants with invasive Candida infections.
Pediatr Infect Dis J. 2012 May;31(5):439-43. doi: 10.1097/INF.0b013e3182467a72.
4
Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.
Antimicrob Agents Chemother. 2011 Dec;55(12):5780-9. doi: 10.1128/AAC.05010-11. Epub 2011 Sep 12.
5
Investigation of a cluster of cutaneous aspergillosis in a neonatal intensive care unit.
J Hosp Infect. 2011 Dec;79(4):344-8. doi: 10.1016/j.jhin.2011.06.012. Epub 2011 Aug 12.
6
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.
Clin Pharmacol Ther. 2011 May;89(5):702-7. doi: 10.1038/clpt.2011.26. Epub 2011 Mar 16.
7
Safety of micafungin in infants: insights into optimal dosing.
Expert Opin Drug Saf. 2011 Mar;10(2):281-6. doi: 10.1517/14740338.2011.545345. Epub 2011 Jan 13.
8
Fluconazole loading dose pharmacokinetics and safety in infants.
Pediatr Infect Dis J. 2011 May;30(5):375-8. doi: 10.1097/INF.0b013e318202cbb3.
9
Voriconazole pharmacokinetics and pharmacodynamics in children.
Clin Infect Dis. 2010 Jan 1;50(1):27-36. doi: 10.1086/648679.
10
Nephrotoxicity associated with amphotericin B deoxycholate in neonates.
Pediatr Infect Dis J. 2009 Dec;28(12):1061-3. doi: 10.1097/INF.0b013e3181af6201.
Zotero 插件